1. Home
  2. SE vs REGN Comparison

SE vs REGN Comparison

Compare SE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sea Limited each representing one

SE

Sea Limited each representing one

HOLD

Current Price

$92.35

Market Cap

77.8B

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$759.58

Market Cap

79.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SE
REGN
Founded
2009
1988
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.8B
79.4B
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
SE
REGN
Price
$92.35
$759.58
Analyst Decision
Strong Buy
Buy
Analyst Count
11
23
Target Price
$179.54
$815.04
AVG Volume (30 Days)
6.9M
638.2K
Earning Date
01-01-0001
04-16-2026
Dividend Yield
N/A
0.49%
EPS Growth
N/A
8.19
EPS
N/A
41.48
Revenue
N/A
$5,872,227,000.00
Revenue This Year
$25.20
$11.69
Revenue Next Year
$17.80
$10.12
P/E Ratio
$49.15
$18.41
Revenue Growth
N/A
20.82
52 Week Low
$77.05
$476.49
52 Week High
$199.30
$821.11

Technical Indicators

Market Signals
Indicator
SE
REGN
Relative Strength Index (RSI) 34.73 45.70
Support Level N/A $740.39
Resistance Level $161.37 $786.67
Average True Range (ATR) 4.96 21.54
MACD -1.41 -2.98
Stochastic Oscillator 37.87 18.91

Price Performance

Historical Comparison
SE
REGN

About SE Sea Limited each representing one

Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid C2C and B2C marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue generating game. Sea's third business, SeaMoney, provides lending, payment, digital banking, and insurance services.As of March 31, 2025, Forrest Xiaodong Li, the founder, chairman and CEO, owned 59.1% of voting power. Tencent owned 18.5% of issued shares with no voting power.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: